Skip to main content
Premium Trial:

Request an Annual Quote

Tm Bioscience Posts Higher Q3 Revenues, Net Loss

NEW YORK, Nov. 7 (GenomeWeb News) - Tm Bioscience reported today a doubling of its third-quarter revenues, despite a slight increase in its net loss, as research and development spending dropped about 43 percent.


For the third quarter, Tm's revenues jumped to $2.2 million from $1.1 million in the year-ago period.


The company's net loss for the quarter inched up to $3.1 million, or $.07 per share, from $3 million, or $.09 per share, a year earlier.


Tm's R&S costs in the third quarter dropped to $661,963 from about $1.2 million in the same quarter last year, although total expenses rose to roughly $4.5 million from about $4 million as the company added employees in the marketing and business development, finance and administration, technical support, and medical and regulatory areas.


As of Sept. 30, Tm had cash and cash equivalents totaling $537,768.  


The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.